PaxMedica Inc. PXMD Archives - Page 2 of 6

WednesdayMay 01, 2024 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA

PaxMedica has completed its three registration/validation batches of PAX-101, an IV formulation of suramin The completed batches are a significant step toward submitting a New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2024 PaxMedica aims to establish a sustainable global supply chain for PAX-101 and to advance research and clinical trials targeting Autism Spectrum Disorder (“ASD”), demonstrating a steadfast commitment to addressing complex neurological conditions The ASD treatment market size was valued at $6.94 billion in 2022 and is projected to grow to $13.14 billion by 2030 PaxMedica (NASDAQ: PXMD), a biopharmaceutical company…

WednesdayApr 24, 2024 12:00 pm

“Urgent Action: PaxMedica Inc. (NASDAQ: PXMD) Addresses Medical Crisis in Malawi”

In recent developments, PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, has taken swift action to address a pressing medical situation unfolding in Malawi, East Africa. The Ministry of Health (“MOH”) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping sickness crisis affecting the region. PaxMedica swiftly responded to this call for help by committing to provide emergency access to its recently completed registration batches of PAX-101, an IV form of suramin. This decision underscores PaxMedica's dedication to mitigating the devastating impact of sleeping sickness…

TuesdayApr 23, 2024 3:43 pm

QualityStocksNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Responds to Emergency Request for IV Suramin, Commits to Provide Immediate Access to PAX-101

PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health (“MOH”) of Malawi, a country in east Africa. The request seeks emergency access to PaxMedica’s recently completed registration batches of PAX-101 (“IV suramin”) to address the critical shortage of medications required to combat the life-threatening sleeping sickness, also known as Trypanosoma brucei rhodesiense, Human African trypanosomiasis (“TBr HAT”), crisis in the region. “The emergency request from the Ministry of Health of Malawi underscores the critical need…

FridayApr 05, 2024 12:13 pm

QualityStocksNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Developing Robust Product Lineup to Address ASD, Associated Neurodevelopmental Conditions

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address the unmet medical needs of ASD, bringing hope to millions. “ASD is a developmental disorder affecting how individuals interact with other people, behavior, communication, and learning. This disorder can be diagnosed at any age, but symptoms often appear in the first two years of life. There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current…

ThursdayMar 21, 2024 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium

Autism (“ASD”) is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a greater than 780% increase in the number of autism cases PaxMedica is focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms The ASD therapeutics market was valued at $2.01 billion in 2023 and is expected to reach $3.42 billion by 2030, growing at a CAGR of 7.9% There is currently no approved pharmacologic treatment targeting the cause and symptoms. Current treatments only address the…

WednesdayMar 20, 2024 1:40 pm

QualityStocksNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”), is focusing its lead program on autism spectrum disorder (“ASD”), for which there is no approved pharmacologic treatment targeting cause and symptoms. “The current ASD treatments only address the symptoms of the condition but do not target the pathophysiology itself. PaxMedica is on a promising path to address the unmet medical needs of families with ASD – bringing hope to millions,” a recent article reads. “PaxMedica is using existing research on a drug called suramin, initially created to treat a disease called Human African…

WednesdayMar 13, 2024 4:11 pm

QualityStocksNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Shares Vision, Innovations in ASD Treatments in Updated Company Presentation

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. The comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in autism spectrum disorder (“ASD”) therapeutics, and its commitment to addressing unmet needs within the ASD community. “PaxMedica is pleased to share our vision and progress with the wider community,” said Howard Weisman, chairman and CEO of PaxMedica. “We believe that our work has the potential to transform the treatment landscape for ASD, offering a new horizon of hope and support for affected individuals and their loved ones.” To…

FridayMar 08, 2024 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Pursues Autism Treatment as Diagnostic App Shows Promise to Effective ASD Diagnosis

One in 36 children are diagnosed with autism spectrum disorder (“ASD”) – with ASD four times more common among boys than girls The SenseToKnow app accurately predicted eventual autism diagnoses in a group of 475 children – according to the study, performance was similar across sex, race, and ethnicity PaxMedica is leveraging historical data on the drug suramin to fund trials aimed at treating Autism Spectrum Disorder and Fragile X-Associated Tremor/Ataxia Syndrome According to the CDC, about 1 in 36 children are diagnosed with autism spectrum disorder (“ASD”) – with ASD four times more common among boys than girls (https://ibn.fm/06kly).…

FridayMar 01, 2024 2:02 pm

QualityStocksNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Committed to Developing Groundbreaking Therapies, Transformative Solutions

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address unmet medical needs of ASD patients. “The prevalence of ASD in the United States has risen to approximately 1 in 36 children, according to the Centers for Disease Control and Prevention (‘CDC’). There are currently no approved pharmacologic treatments that target the causes and symptoms of ASD – the treatment available on the market addresses symptoms of the…

TuesdayFeb 20, 2024 9:45 am

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline of Products to Address Prevalence and Unmet Medical Needs of Autism Spectrum Disorder

The CDC estimates that the prevalence of ASD in the United States is 1 in 36 children, with no approved pharmacologic treatments targeting the cause and symptoms PaxMedica is developing novel anti-purinergic therapies for the treatment of ASD and other serious conditions with intractable neurologic symptoms, and is on a promising path to address the unmet medical needs and bring hope to millions Company CEO Howard Weisman recently shared insights into PaxMedica’s achievements and advancements in a Fireside Chat video, underscoring the company’s commitment to groundbreaking therapies and transformative solutions The prevalence of autism spectrum disorder (“ASD”) in the United…

Site Search

Company Search

Tag: PaxMedica Inc. PXMD